Nykode Therapeutics – invitation to Q3 2023 financial results presentation Posted on November 9, 2023 (November 9, 2023) by Alexandra Deschner […] Read More… from Nykode Therapeutics – invitation to Q3 2023 financial results presentation
Nykode Therapeutics to Present at Jefferies Healthcare Conference Posted on November 7, 2023 (November 7, 2023) by Alexandra Deschner […] Read More… from Nykode Therapeutics to Present at Jefferies Healthcare Conference
SITC – 2023 | Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab Posted on October 31, 2023 (October 31, 2023) by Kim Larsen […] Read More… from SITC – 2023 | Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab
Nykode Therapeutics ASA – Private Placement Completed Posted on October 25, 2023 (October 25, 2023) by Kim Larsen […] Read More… from Nykode Therapeutics ASA – Private Placement Completed
Nykode Therapeutics ASA – Contemplated Private Placement Posted on October 24, 2023 (October 25, 2023) by Kim Larsen […] Read More… from Nykode Therapeutics ASA – Contemplated Private Placement
Nykode Therapeutics – Update on process with the Norwegian Tax Authorities Posted on October 23, 2023 (October 24, 2023) by Kim Larsen […] Read More… from Nykode Therapeutics – Update on process with the Norwegian Tax Authorities
RNA Cancer Vaccines Summit – 2023 | Antigen presenting cell targeted vaccines Posted on October 12, 2023 (October 12, 2023) by Kim Larsen […] Read More… from RNA Cancer Vaccines Summit – 2023 | Antigen presenting cell targeted vaccines
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston Posted on October 10, 2023 (October 10, 2023) by Kim Larsen […] Read More… from Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston
AACR Special Conference on Tumor Immunology and Immunotherapy – 2023 | High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T-cell responses in VB10.16 vaccinated advanced cervical cancer patients Posted on October 2, 2023 (October 2, 2023) by Kim Larsen […] Read More… from AACR Special Conference on Tumor Immunology and Immunotherapy – 2023 | High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T-cell responses in VB10.16 vaccinated advanced cervical cancer patients
Nykode Therapeutics Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer Posted on September 29, 2023 (September 29, 2023) by Kim Larsen […] Read More… from Nykode Therapeutics Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer